1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:
Elanco GmbH, Heinz-Lohmann-Str. 4, 27472 Cuxhaven, Germany

Manufacturer responsible for batch release:
Elanco France S.A.S., 26 rue de la Chapelle, 68330 Huningue, France

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Credelio 12 mg chewable tablets for cats (0.5–2.0 kg)
Credelio 48 mg chewable tablets for cats (>2.0–8.0 kg)

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Each chewable tablet contains:

<table>
<thead>
<tr>
<th>Credelio chewable tablets</th>
<th>lotilaner (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>for cats (0.5–2.0 kg)</td>
<td>12</td>
</tr>
<tr>
<td>for cats (&gt;2–8.0 kg)</td>
<td>48</td>
</tr>
</tbody>
</table>

White to brownish round chewable tablets with brownish spots.

4. INDICATION(S)

For the treatment of flea and tick infestations on cats.
This veterinary medicinal product provides immediate and persistent killing activity for 1 month against fleas (Ctenocephalides felis and C. canis) and ticks (Ixodes ricinus).
Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.
The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).

5. CONTRAINDICATIONS

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

6. ADVERSE REACTIONS

Vomiting has been reported very rarely based on post marketing safety experience and typically resolves without treatment.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

7. TARGET SPECIES

Cats

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

For oral use.
The flavoured veterinary medicinal product should be administered in accordance with the following table to ensure a single dose of 6 to 24 mg lotilaner/kg bodyweight.

<table>
<thead>
<tr>
<th>Body weight of cat (kg)</th>
<th>Strength and number of tablets to be administered</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Credelio 12 mg Credelio 48 mg</td>
</tr>
<tr>
<td>0.5–2.0</td>
<td>1</td>
</tr>
<tr>
<td>&gt;2.0–8.0</td>
<td>1</td>
</tr>
<tr>
<td>&gt;8.0</td>
<td>Appropriate combination of tablets</td>
</tr>
</tbody>
</table>

For cats of more than 8 kg body weight use an appropriate combination of available strengths to achieve the recommended dose of 6–24 mg/kg.

9. ADVICE ON CORRECT ADMINISTRATION

Administer the veterinary medicinal product with food or within 30 minutes after feeding.
For optimal control of tick and flea infestations, the veterinary medicinal product should be administered at monthly intervals and continued throughout the flea and/or tick season based on local epidemiological situations.
10. WITHDRAWAL PERIOD(S)

Not applicable.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.
This veterinary medicinal product does not require any special storage conditions.
Do not use this veterinary medicinal product after the expiry date which is
stated on the carton box and blister after EXP. The expiry date refers to the
last day of that month.

12. SPECIAL WARNING(S)

Special warnings for each target species:
Parasites need to start feeding on the host to become exposed to lotilaner;
therefore, the risk of the transmission of parasite borne diseases cannot be
completely excluded.
Acceptable levels of efficacy may not be achieved if the veterinary
medicinal product is not administered with food or within 30
minutes after feeding.
Due to insufficient data to support efficacy against ticks in
young cats, this product is not recommended for the treatment of
ticks in kittens 5 months of age or younger.
Special precautions for use in animals:
All safety and efficacy data have been acquired from cats and kittens 8 weeks of
age and older and
0.5 kg of body weight and greater. Use of this veterinary medicinal product in
kittens younger than 8 weeks of age or less than 0.5 kg of body weight should
be based on a benefit-risk assessment by the responsible veterinarian.
Special precautions to be taken by the person administering the veterinary
medicinal product to animals:
Wash hands after handling the product.
In case of accidental ingestion, seek medical advice immediately and show the
package leaflet or label to the physician.
Pregnancy and lactation:
Laboratory studies in rats have not produced any evidence of teratogenic effects.
The safety of the veterinary medicinal product in cats has not been established
during pregnancy and lactation. Use only accordingly to the benefit-risk assessment
by the responsible veterinarian.
Fertility:
Laboratory studies in rats have not produced any evidence of any adverse effect on
the reproductive capacity of males and females.
The safety of the veterinary medicinal product in breeding queens has not
been established. Use only accordingly to the benefit-risk assessment by the
responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:
None known. During clinical testing, no interactions between Credelio
chewable tablets and routinely used veterinary medicinal products were
observed.

Overdose (symptoms, emergency procedures, antidotes):
No adverse reactions were observed following oral administration to kittens
aged 8 weeks and weighing 0.5 kg treated with overdoses of more than 5
times the maximum recommended dose rate (130 mg lotilaner/kg bodyweight)
on eight occasions at monthly intervals.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED
PRODUCT OR WASTEMATERIALS, IF ANY

Medicines should not be disposed of via wastewater or household waste.
Ask your veterinary surgeon how to dispose of medicines no longer required.
These measures should help to protect the environment.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

June 2021

15. OTHER INFORMATION

Lotilaner, a pure enantiomer from the isoxazoline class, is active against fleas
(CTenoccephalides felisand Ctenocephalides canis) and ticks (Ixodes ricinus).
Lotilaner is a potent inhibitor of gamma–aminobutyric acid (GABA)-gated
chloride channels, resulting in rapid death of ticks and fleas. In in vitro
studies, the activity of lotilaner against some arthropod species was not affected by
resistance to organochlorines (cyclodiene, e.g. dieldrin), phenylpyrazoles
(e.g. fipronil), neonicotinoids (e.g. imidacloprid), formamidines (e.g. amitraz)
and pyrethroids (e.g. cypermethrin).

For fleas, the onset of efficacy is within 12 hours of attachment for one month
after product administration. Fleas on the animal prior to administration
are killed within 18 hours.

For ticks, the onset of efficacy is within 24 hours of attachment for one month
after product administration. Existing ticks on the animal prior to administration
are killed within 18 hours.

The veterinary medicinal product kills existing and newly emerged fleas on
cats before they can lay eggs. Therefore, the product breaks the flea life cycle
and prevents environmental flea contamination in areas to which the cat has
access.

Each strength of Credelio chewable tablets for cats is available in
pack sizes of 1, 3 or 6 tablets. Not all pack sizes may be marketed.